Campbell David Alan

JANX CEO David Alan sold 25,000 shares at $56.19 on 2024-12-24; stock now $54.10, down -19.1% from 52-week high.

David Alan, President and CEO of Janux Therapeutics, sold 25,000 shares (reducing his holdings from 242,054 to 217,054 shares, a 10.3% reduction) at $56.19 per share on 2024-12-24. The stock has since declined to $54.10, situating this sale near the upper range of the 52-week span (down 19.1% from the $66.84 high but up 16.6% over the prior 30 days). This marks his fifth discrete open-market sale at JANX within five weeks, with the prior four sales showing mixed near-term outcomes: two posted positive 30-day returns (+9.2% and +7.9%) while two showed negative 30-day returns (-14.0% and -12.8%). The company remains unprofitable (most recent quarter net income: $-28,059,000.00), with annual revenue declining 6.1% year-over-year, providing a backdrop of operational stress against which repeated CEO sales warrant investor scrutiny of upcoming earnings and cash-burn trajectory.

JANX CEO David Campbell sold 15,000 shares at $67.00 for $1.0M on 2024-12-03; stock now at $59.86.

Campbell David Alan, President and CEO, sold 15,000 shares at $67.00, reducing his holdings from 257.1K to 242.1K shares (a -5.8% decrease). The sale occurred near the 52-week high of $64.78, and the stock has since declined 7.6% from that peak to $59.86 current price. At JANX specifically, the CEO's 5 prior trades show mixed outcomes: recent October sales yielded negative 30-day returns of -12.8% and -14.0%, while a September sale returned +14.0%, indicating no clear pattern of timing acuity. The company's fundamentals remain challenged: latest quarterly revenue stands at $439.0K with a net loss of $28.1M, annual revenue declined -6.1%, and the firm remains unprofitable on a full-year basis with a $3.1B market cap. The timing and magnitude of this sale against deteriorating fundamentals warrant investor attention to whether the CEO is adjusting his exposure amid operational headwinds.

CEO Campbell David Alan sells 25,000 JANX shares at $51.60 blended average; stock now at $46.39, down 14.7% in 30 days.

Campbell David Alan executed two separate sales totaling 25,000 shares for $1,289,878.73 on November 25, 2024, at an average price of $51.60. The stock has declined 14.7% over the subsequent 30-day period and now trades at $46.39, placing it 28.4% below its 52-week high of $64.78. This sale represents an 8.9% reduction in the insider's holdings from 282.1K to 257.1K shares. Notably, JANX is unprofitable with a net income of $-28.1M in its most recent full fiscal year, operates on minimal quarterly revenue of $439.0K, and has experienced an annual revenue decline of 6.1% year-over-year. The insider's prior two trades at this ticker (both on 2024-10-28) posted negative 30-day returns of 12.8% and 14.0%, consistent with the recent downward price momentum.

CEO Campbell David Alan sells 25,000 JANX shares for $1,338,558.90; 3rd sale in one month as stock surges +23.2% in 30 days.

Campbell David Alan, President and CEO, executed 2 separate sales on 2024-10-28 totaling 25,000 shares (25.0K shares) for $1,338,558.90 ($1.3M), reducing his post-transaction holdings to 282,054 shares (282.1K shares) from 307,054 shares (307.1K shares). This represents his third sale in as many days—following two sales on 2024-09-27—during a period when JANX stock has gained +23.2% over 30 days and +35.0% over 90 days, reaching near its 52-week high of $64.78. The company remains unprofitable (net income $-5,959,000.00 ($-6.0M) in the latest quarter) with declining annual revenue (-6.1% year-over-year), yet the stock has appreciated significantly. Prior sales by this insider at JANX have shown positive 30-day returns (15.9%, 14.0%, 11.6%), suggesting his recent sales preceded further price appreciation rather than declines. The concentrated timing of these three sales during a sustained rally warrants close monitoring of whether this pattern reflects circumstances specific to the insider, the company, or market conditions.

JANX CEO Campbell sold 25,000 shares for $1.2M at $46.31 avg; retains 307.1K shares

Campbell David Alan, President and CEO, executed 3 separate sales totaling 25,000 shares for $1,157,641.43 on 2024-09-27, reducing his holdings by 7.5% while retaining 307.1K shares. The blended average price of $46.31 is closely aligned with the current price of $46.25, indicating execution near current market levels. Against the company's fundamental backdrop—unprofitable full-year performance with net income of $-5,959,000.00 and annual revenue decline of 6.1%—a CEO equity reduction of this scale is notable for its timing relative to operational headwinds. The stock trades -28.6% from its 52-week high of $64.78, having risen +10.4% over the prior 90 days; the sale occurs within this recent upward move but well below prior peaks.